SUBSCRIBE
SUBSCRIBE

MyoKardia, Inc

NEWS
MyoKardia, Inc. was acquired by Bristol Myers Squibb (BMS) in 2020.
Keitma / Shutterstock
Business
Sanofi Unloads Programs to Acer Therapeutics and MyoKardia
Acer Therapeutics, headquartered in Newton, Mass., in-licensed osanetant, a clinical-stage, selective, non-peptide tachykinin NK3 receptor antagonist from Paris-based Sanofi.
January 2, 2019
 · 
4 min read
 · 
Mark Terry
Business
Where Are They Now? Top 3 Biotech Startups From NextGen Bio Class of 2015
Every year, BioSpace analyzes the biotech industry, looking for the hot new biotech startups to watch. Here’s a look at the top 3 companies from the Top 30 Life Science Startups to Watch in the U.S. from 2015.
November 28, 2018
 · 
4 min read
 · 
Mark Terry
Primary Logo
Drug Development
MyoKardia Begins Patient Dosing in Phase 1b Clinical Study of MYK-491 in Dilated Cardiomyopathy Patients
MyoKardia, Inc. (Nasdaq:MYOK), a clinical-stage biopharmaceutical company pioneering a precision medicine approach for the treatment of heritable cardiovascular diseases, today announced that dosing has commenced in a Phase 1b single-ascending dose patient study of its investigational drug candidate MYK-491.
July 27, 2018
 · 
7 min read
Top Countries With the Highest Paid Salaries for S
Drug Development
MyoKardia Sees Positive Results in Mid-Stage Heart Trial
MyoKardia Inc. revealed positive results from a mid-stage obstructive hypertrophic cardiomyopathy trial.
March 9, 2018
 · 
2 min read
 · 
Alex Keown
Why This Biotech, Up 300% Since May, Could be the Next Big M&A Target
Drug Development
MyoKardia Shares Surge on Positive Phase II Results for Heart Muscle Disease
August 7, 2017
 · 
3 min read
Astellas Pharma, Proteostasis Therapeutics Forge $1.2 Billion Genetic Disease Drug Development Pact
Business
Bay Area MyoKardia Snags $46 Million in Series B Financing Amid Rumors of Future IPO
April 30, 2015
 · 
2 min read
Snag a Job: Here's How CSL Behring Makes Hiring Decisions
Biotech Bay
HR Exec Reveals In-Demand Jobs at MyoKardia
February 17, 2015
 · 
3 min read
Mylan Inc., Theravance, Inc. Partner Up for $265 Million COPD Pact
Business
Bay Area Startup MyoKardia Forges $200 Million Heart Disease Pact With Sanofi (France)
September 17, 2014
 · 
1 min read
Load More
AWARDS
  • NextGen Class of 2015
IN THE PRESS
Biotech Bay
Data from MAVERICK-HCM Study of Mavacamten in Non-Obstructive Hypertrophic Cardiomyopathy Selected for Virtual Late-Breaker Presentation at the ACC’s 69th Annual Scientific Session Together with World Congress of Cardiology
March 19, 2020
 · 
3 min read
Business
MyoKardia Reports Fourth Quarter and Full Year 2019 Financial Results
February 27, 2020
 · 
12 min read
Biotech Bay
MyoKardia to Present at 40th Annual Cowen Health Care Conference
February 24, 2020
 · 
1 min read
Business
MyoKardia to Report Fourth Quarter and Full Year 2019 Financial Results on Thursday, February 27, 2020
February 20, 2020
 · 
1 min read
Biotech Bay
MyoKardia to Present at 38th Annual J.P. Morgan Healthcare Conference
January 6, 2020
 · 
1 min read
Biotech Bay
MyoKardia to Present at Evercore ISI 2nd Annual HealthCONx Conference
November 27, 2019
 · 
1 min read
Drug Development
MyoKardia Announces Positive Topline Data from its Phase 2 MAVERICK-HCM Clinical Trial of Mavacamten
November 11, 2019
 · 
11 min read
Biotech Bay
MyoKardia Announces 48-week Data from PIONEER-OLE Study of Mavacamten
November 11, 2019
 · 
12 min read
Biotech Bay
MyoKardia to Present at Credit Suisse 28th Annual Healthcare Conference
November 6, 2019
 · 
1 min read
Business
MyoKardia Reports Third Quarter 2019 Financial Results
November 4, 2019
 · 
12 min read
Load More